vs
BLACKLINE, INC.（BL）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是BLACKLINE, INC.的1.2倍（$219.9M vs $183.2M），BLACKLINE, INC.净利率更高（2.7% vs -1.0%，领先3.7%），BLACKLINE, INC.同比增速更快（8.1% vs 2.0%），BLACKLINE, INC.自由现金流更多（$26.1M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 7.9%）
BlackLine是一家美国企业级软件公司，总部位于洛杉矶，在全球设有17个办事处，专注于开发云服务，可实现财务结账全流程自动化与管理，同时覆盖财务合并、发票到回款流程及公司间会计核算等业务场景。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
BL vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.2倍
$183.2M
营收增速更快
BL
高出6.1%
2.0%
净利率更高
BL
高出3.7%
-1.0%
自由现金流更多
BL
多$9.2M
$16.8M
两年增速更快
OFIX
近两年复合增速
7.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.2M | $219.9M |
| 净利润 | $4.9M | $-2.2M |
| 毛利率 | 75.2% | 71.1% |
| 营业利润率 | 3.7% | 0.2% |
| 净利率 | 2.7% | -1.0% |
| 营收同比 | 8.1% | 2.0% |
| 净利润同比 | -91.3% | 92.4% |
| 每股收益（稀释后） | $0.07 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLOFIX
| Q4 25 | $183.2M | $219.9M | ||
| Q3 25 | $178.3M | $205.6M | ||
| Q2 25 | $172.0M | $203.1M | ||
| Q1 25 | $166.9M | $193.6M | ||
| Q4 24 | $169.5M | $215.7M | ||
| Q3 24 | $165.9M | $196.6M | ||
| Q2 24 | $160.5M | $198.6M | ||
| Q1 24 | $157.5M | $188.6M |
净利润BLOFIX
| Q4 25 | $4.9M | $-2.2M | ||
| Q3 25 | $5.3M | $-22.8M | ||
| Q2 25 | $8.3M | $-14.1M | ||
| Q1 25 | $6.1M | $-53.1M | ||
| Q4 24 | $56.4M | $-29.1M | ||
| Q3 24 | $17.2M | $-27.4M | ||
| Q2 24 | $76.7M | $-33.4M | ||
| Q1 24 | $10.8M | $-36.0M |
毛利率BLOFIX
| Q4 25 | 75.2% | 71.1% | ||
| Q3 25 | 75.1% | 72.2% | ||
| Q2 25 | 75.2% | 68.7% | ||
| Q1 25 | 75.5% | 62.8% | ||
| Q4 24 | 75.6% | 69.0% | ||
| Q3 24 | 75.2% | 68.7% | ||
| Q2 24 | 74.9% | 67.8% | ||
| Q1 24 | 75.2% | 67.5% |
营业利润率BLOFIX
| Q4 25 | 3.7% | 0.2% | ||
| Q3 25 | 4.3% | -8.3% | ||
| Q2 25 | 4.4% | -7.9% | ||
| Q1 25 | 2.1% | -25.2% | ||
| Q4 24 | 3.7% | -5.3% | ||
| Q3 24 | 5.0% | -9.6% | ||
| Q2 24 | 1.4% | -12.5% | ||
| Q1 24 | 1.1% | -15.6% |
净利率BLOFIX
| Q4 25 | 2.7% | -1.0% | ||
| Q3 25 | 3.0% | -11.1% | ||
| Q2 25 | 4.8% | -6.9% | ||
| Q1 25 | 3.6% | -27.4% | ||
| Q4 24 | 33.3% | -13.5% | ||
| Q3 24 | 10.4% | -13.9% | ||
| Q2 24 | 47.8% | -16.8% | ||
| Q1 24 | 6.9% | -19.1% |
每股收益（稀释后）BLOFIX
| Q4 25 | $0.07 | $-0.05 | ||
| Q3 25 | $0.09 | $-0.57 | ||
| Q2 25 | $0.13 | $-0.36 | ||
| Q1 25 | $0.10 | $-1.35 | ||
| Q4 24 | $0.79 | $-0.76 | ||
| Q3 24 | $0.27 | $-0.71 | ||
| Q2 24 | $0.22 | $-0.88 | ||
| Q1 24 | $0.17 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $390.0M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $332.3M | $450.0M |
| 总资产 | $1.8B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLOFIX
| Q4 25 | $390.0M | $82.0M | ||
| Q3 25 | $419.9M | $62.9M | ||
| Q2 25 | $459.1M | $65.6M | ||
| Q1 25 | $479.5M | $58.0M | ||
| Q4 24 | $885.9M | $83.2M | ||
| Q3 24 | $725.3M | $30.1M | ||
| Q2 24 | $616.6M | $26.4M | ||
| Q1 24 | $331.4M | $27.0M |
总债务BLOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益BLOFIX
| Q4 25 | $332.3M | $450.0M | ||
| Q3 25 | $328.3M | $442.5M | ||
| Q2 25 | $414.0M | $458.3M | ||
| Q1 25 | $417.9M | $458.3M | ||
| Q4 24 | $446.7M | $503.1M | ||
| Q3 24 | $367.9M | $525.9M | ||
| Q2 24 | $325.8M | $546.0M | ||
| Q1 24 | $279.8M | $570.3M |
总资产BLOFIX
| Q4 25 | $1.8B | $850.6M | ||
| Q3 25 | $1.7B | $832.6M | ||
| Q2 25 | $1.8B | $837.2M | ||
| Q1 25 | $1.8B | $823.1M | ||
| Q4 24 | $1.8B | $893.3M | ||
| Q3 24 | $1.7B | $867.9M | ||
| Q2 24 | $1.9B | $882.0M | ||
| Q1 24 | $2.1B | $906.0M |
负债/权益比BLOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $26.7M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $26.1M | $16.8M |
| 自由现金流率自由现金流/营收 | 14.2% | 7.6% |
| 资本支出强度资本支出/营收 | 0.3% | 4.9% |
| 现金转化率经营现金流/净利润 | 5.46× | — |
| 过去12个月自由现金流最近4个季度 | $161.5M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流BLOFIX
| Q4 25 | $26.7M | $27.7M | ||
| Q3 25 | $63.8M | $12.4M | ||
| Q2 25 | $32.3M | $11.6M | ||
| Q1 25 | $46.7M | $-18.4M | ||
| Q4 24 | $43.8M | $23.7M | ||
| Q3 24 | $55.9M | $11.7M | ||
| Q2 24 | $40.7M | $9.0M | ||
| Q1 24 | $50.4M | $-18.6M |
自由现金流BLOFIX
| Q4 25 | $26.1M | $16.8M | ||
| Q3 25 | $63.3M | $2.5M | ||
| Q2 25 | $31.4M | $4.5M | ||
| Q1 25 | $40.8M | $-25.1M | ||
| Q4 24 | $43.0M | $15.2M | ||
| Q3 24 | $55.5M | $6.3M | ||
| Q2 24 | $40.0M | $-360.0K | ||
| Q1 24 | $50.1M | $-29.1M |
自由现金流率BLOFIX
| Q4 25 | 14.2% | 7.6% | ||
| Q3 25 | 35.5% | 1.2% | ||
| Q2 25 | 18.2% | 2.2% | ||
| Q1 25 | 24.4% | -13.0% | ||
| Q4 24 | 25.4% | 7.0% | ||
| Q3 24 | 33.5% | 3.2% | ||
| Q2 24 | 24.9% | -0.2% | ||
| Q1 24 | 31.8% | -15.4% |
资本支出强度BLOFIX
| Q4 25 | 0.3% | 4.9% | ||
| Q3 25 | 0.3% | 4.8% | ||
| Q2 25 | 0.6% | 3.5% | ||
| Q1 25 | 3.6% | 3.5% | ||
| Q4 24 | 0.4% | 4.0% | ||
| Q3 24 | 0.2% | 2.7% | ||
| Q2 24 | 0.4% | 4.7% | ||
| Q1 24 | 0.2% | 5.6% |
现金转化率BLOFIX
| Q4 25 | 5.46× | — | ||
| Q3 25 | 12.07× | — | ||
| Q2 25 | 3.90× | — | ||
| Q1 25 | 7.72× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | 3.24× | — | ||
| Q2 24 | 0.53× | — | ||
| Q1 24 | 4.66× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BL
| Subscription And Circulation | $173.2M | 95% |
| Technology Service | $10.0M | 5% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
